世界の持続皮下インスリン注入療法(CSII)市場(~2027):製品別、患者タイプ別、エンドユーザー別、地域別

【英語タイトル】Continuous Subcutaneous Insulin Infusion Market Research Report by Product, Patient Type, End-user, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが出版した調査資料(MRC2305D148)・商品コード:MRC2305D148
・発行会社(調査会社):360iResearch
・発行日:2022年10月
・ページ数:226
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3日)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用、印刷可)USD4,949 ⇒換算¥752,248見積依頼/購入/質問フォーム
Enterprise License(企業利用、印刷可)USD9,949 ⇒換算¥1,512,248見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

360iResearch社は、2021年に2,173.67百万ドルであった世界の持続皮下インスリン注入療法(CSII)市場規模が、2022年に2,431.96百万ドルに成長し、更に年平均12.05%拡大して2027年までに4,304.14百万ドルに達すると予測しています。当市場調査レポートでは、持続皮下インスリン注入療法(CSII)の世界市場を多角的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別(パッチ式ポンプ、接続式ポンプ)分析、患者タイプ別(1型糖尿病患者、2型糖尿病患者)分析、エンドユーザー別(在宅医療、病院、研究室)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの内容を掲載しています。また、当書内の企業情報には、Apex Medical Corp.、Byram Healthcare Centers, Inc.、Cellenovo、Cellnovo Group、CeQur SA、Dana Diabecare RS、DEKA Research & Development Corporation、DexCom, Inc.、Edgepark、IA Collaborative Holdings, LLC、Kaleido、Medtronic plcなどが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の持続皮下インスリン注入療法(CSII)市場規模:製品別
- パッチ式ポンプの市場規模
- 接続式ポンプの市場規模
・世界の持続皮下インスリン注入療法(CSII)市場規模:患者タイプ別
- 1型糖尿病患者における市場規模
- 2型糖尿病患者における市場規模
・世界の持続皮下インスリン注入療法(CSII)市場規模:エンドユーザー別
- 在宅医療における市場規模
- 病院における市場規模
- 研究室における市場規模
・世界の持続皮下インスリン注入療法(CSII)市場規模:地域別
- 南北アメリカの持続皮下インスリン注入療法(CSII)市場規模
アメリカの持続皮下インスリン注入療法(CSII)市場規模
カナダの持続皮下インスリン注入療法(CSII)市場規模
ブラジルの持続皮下インスリン注入療法(CSII)市場規模
...
- アジア太平洋の持続皮下インスリン注入療法(CSII)市場規模
日本の持続皮下インスリン注入療法(CSII)市場規模
中国の持続皮下インスリン注入療法(CSII)市場規模
インドの持続皮下インスリン注入療法(CSII)市場規模
韓国の持続皮下インスリン注入療法(CSII)市場規模
台湾の持続皮下インスリン注入療法(CSII)市場規模
...
- ヨーロッパ/中東/アフリカの持続皮下インスリン注入療法(CSII)市場規模
イギリスの持続皮下インスリン注入療法(CSII)市場規模
ドイツの持続皮下インスリン注入療法(CSII)市場規模
フランスの持続皮下インスリン注入療法(CSII)市場規模
ロシアの持続皮下インスリン注入療法(CSII)市場規模
...
- その他地域の持続皮下インスリン注入療法(CSII)市場規模
・競争状況
・企業情報

The Global Continuous Subcutaneous Insulin Infusion Market size was estimated at USD 2,173.67 million in 2021 and expected to reach USD 2,431.96 million in 2022, and is projected to grow at a CAGR 12.05% to reach USD 4,304.14 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Continuous Subcutaneous Insulin Infusion to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Patch Pumps and Tethered pumps. The Patch Pumps is further studied across Basal, Basal and bolus, and Bous. The Tethered pumps is further studied across Battery, Insulin reservoir and cartridges, and Insulin set insertion devices.

Based on Patient Type, the market was studied across Type 1 diabetes and Type 2 diabetes.

Based on End-user, the market was studied across Homecare, Hospitals, and Laboratory.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Continuous Subcutaneous Insulin Infusion market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Continuous Subcutaneous Insulin Infusion Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Continuous Subcutaneous Insulin Infusion Market, including Apex Medical Corp., Byram Healthcare Centers, Inc., Cellenovo, Cellnovo Group, CeQur SA, Dana Diabecare RS, DEKA Research & Development Corporation, DexCom, Inc., Edgepark, IA Collaborative Holdings, LLC, Kaleido, Medtronic plc, Medtrum Technologies Inc., OpenAPS, Pumps It, Inc., Roche Holding AG, Shanghai Microport Orthopedics, Tandem Diabetes Care, Inc., Tidepool, Valeritus, and Ypsomed Holding.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Continuous Subcutaneous Insulin Infusion Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Continuous Subcutaneous Insulin Infusion Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Continuous Subcutaneous Insulin Infusion Market?
4. What is the competitive strategic window for opportunities in the Global Continuous Subcutaneous Insulin Infusion Market?
5. What are the technology trends and regulatory frameworks in the Global Continuous Subcutaneous Insulin Infusion Market?
6. What is the market share of the leading vendors in the Global Continuous Subcutaneous Insulin Infusion Market?
7. What modes and strategic moves are considered suitable for entering the Global Continuous Subcutaneous Insulin Infusion Market?

❖ レポートの目次 ❖

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of diabetes patients
5.1.1.2. Growing awareness of advanced insulin delivery devices
5.1.1.3. Rising healthcare expenditure pertinent to diabetes globally
5.1.2. Restraints
5.1.2.1. High cost of devices
5.1.2.2. Risk of diabetic ketoacidosis (DKA) and skin infection
5.1.3. Opportunities
5.1.3.1. Emerging technological advancements such as AI and IoT
5.1.3.2. Ongoing rise in the number of product launches by market players
5.1.4. Challenges
5.1.4.1. Possible risks such as diabetic ketoacidosis and hypoglycemia
5.2. Cumulative Impact of COVID-19

6. Continuous Subcutaneous Insulin Infusion Market, by Product
6.1. Introduction
6.2. Patch Pumps
6.3.1. Basal
6.3.2. Basal and bolus
6.3.3. Bous
6.3. Tethered pumps
6.4.1. Battery
6.4.2. Insulin reservoir and cartridges
6.4.3. Insulin set insertion devices

7. Continuous Subcutaneous Insulin Infusion Market, by Patient Type
7.1. Introduction
7.2. Type 1 diabetes
7.3. Type 2 diabetes

8. Continuous Subcutaneous Insulin Infusion Market, by End-user
8.1. Introduction
8.2. Homecare
8.3. Hospitals
8.4. Laboratory

9. Americas Continuous Subcutaneous Insulin Infusion Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Continuous Subcutaneous Insulin Infusion Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Continuous Subcutaneous Insulin Infusion Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Apex Medical Corp.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Byram Healthcare Centers, Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Cellenovo
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Cellnovo Group
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. CeQur SA
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Dana Diabecare RS
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. DEKA Research & Development Corporation
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. DexCom, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Edgepark
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. IA Collaborative Holdings, LLC
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Kaleido
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Medtronic plc
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Medtrum Technologies Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. OpenAPS
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Pumps It, Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Roche Holding AG
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Shanghai Microport Orthopedics
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Tandem Diabetes Care, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Tidepool
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Valeritus
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Ypsomed Holding
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing



★調査レポート[世界の持続皮下インスリン注入療法(CSII)市場(~2027):製品別、患者タイプ別、エンドユーザー別、地域別] (コード:MRC2305D148)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の持続皮下インスリン注入療法(CSII)市場(~2027):製品別、患者タイプ別、エンドユーザー別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆